Delirium market seen reaching $522 million by 2032 as AI diagnostics gain ground

By AI, Created 11:19 AM UTC, May 20, 2026, /AGP/ – Maximize Market Research says the global delirium market was worth $348 million in 2024 and is projected to reach $522 million by 2032. The report points to aging populations, AI-based detection, biomarkers and non-drug ICU protocols as the main forces reshaping delirium care.

Why it matters: - Delirium care is moving from reactive drug treatment toward earlier detection, biomarker testing and non-pharmacological ICU protocols. - The shift could change hospital workflows, especially in intensive care units and geriatric surgery, where delirium drives longer stays and higher costs. - The report argues that hypoactive delirium, the least visible subtype, is becoming the biggest clinical and commercial opportunity.

What happened: - Maximize Market Research valued the global delirium market at $348 million in 2024 and projected it will reach $522 million by 2032, a 5.45% compound annual growth rate. - The report was published May 4, 2026. - The market outlook centers on aging populations, AI-based diagnostic tools and growing concern over hypoactive delirium. - The report also includes a full PDF sample copy and a full market description at the report page.

The details: - Delirium affects up to 80% of ICU patients and about 1 in 5 post-surgical adults over 65, according to the report. - The WHO projects the global population aged 60 and older will reach 1.4 billion by 2030 and 2.1 billion by 2050. - Post-operative delirium can add an estimated $16,000 to $64,000 per patient in avoidable hospital costs. - A 2024 Massachusetts General Hospital study found 68% of surgical patients over 50 developed hypoactive delirium after surgery. - The report says hypoactive delirium is misidentified as sedation or fatigue in more than 70% of cases. - ICU delirium incidence reached up to 46.3% among critically ill patients, based on 2022 data cited from Hindawi. - The report segments the market by type, diagnosis and treatment, and end user. - Type segments include hyperactive, hypoactive and mixed delirium. - End users include hospitals, speciality clinics, homecare and research centers.

Between the lines: - The report frames delirium as a visibility problem as much as a treatment problem, especially because hypoactive cases can be missed during routine care. - Conventional use of haloperidol and first-generation antipsychotics is under pressure as hospitals look for safer and more effective approaches in older adults. - AI tools, wearable monitors and Tele-ICU platforms are creating a diagnostics-first market instead of a medication-first market. - North America leads because of stronger ICU infrastructure, faster AI adoption and standardized Confusion Assessment Method deployment across hospitals. - Asia-Pacific is described as the fastest-growing region because of China’s aging population, India’s hospital buildout and government backing for AI-enabled care. - The report says Ceribell launched a rapid EEG-based seizure and delirium detection tool that cuts bedside setup from 30 minutes to 5 minutes. - Prolira’s DeltaScan uses AI-powered EEG to screen for delirium in under 3 minutes, according to the report. - Philips’ VitalMinds program has been deployed across ICUs in 12 countries and is linked to a 34% reduction in delirium episodes in enrolled ICU patients. - HealthNet Global launched a Tele-ICU program at Apollo Spectra Hospital in India in April 2024. - The report says the ABCDEF bundle is becoming the gold standard for ICU delirium prevention.

What’s next: - Hospitals are expected to keep expanding early-detection systems, including biomarkers such as Neurofilament Light Chain, tau proteins and inflammatory cytokines. - Wearable ICU monitoring and remote neurological surveillance are likely to widen access beyond major hospitals. - Non-drug approaches such as sleep optimization, early mobilization, calming music and light therapy are expected to gain more room in care protocols. - The report expects North America to remain the largest market while Asia-Pacific drives the fastest volume growth through 2032.

The bottom line: - Delirium is becoming a technology-enabled critical care market, not just a pharmacology category. - The biggest change is the push to find and treat hypoactive delirium before it is missed.